Green Light for CVD Data From DECLARE in Dapagliflozin EU Label Green Light for CVD Data From DECLARE in Dapagliflozin EU Label
The EMA CHMP gives green light to change EU label for dapagliflozin (Forxiga, AstraZeneca) for type 2 diabetes to include CV outcomes data from DECLARE-TIMI 58.International Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: AstraZeneca | Cardiology | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart